Xuefeng Zang

751 citations
27 papers · 505 indexed · h-index 11
Topics
MicroRNA in disease regulation (4 papers)Circular RNAs in diseases (4 papers)Sepsis Diagnosis and Treatment (3 papers)
Partner nations
China

In The Last Decade

Xuefeng Zang

25 papers receiving 501 citations

Peers

Xuefeng Zang
Comparison fields: 5 of 79
  • Molecular Biology 275
  • Cancer Research 189
  • Oncology 75
  • Surgery 60
  • Immunology 59
Replace Zhankui Jia with:
Zhankui Jia China
Linhui Yuan China
Nobufumi Sekino Japan
Jianlin Shao China
Chengzhi Ding China
Fanjian Li China
Ainhoa Alberro Spain
Julie Ahn United States
Xuefeng Zang relative to Zhankui Jia China Zhankui Jia's profile →
Citations per field
00.5×1.5×1.9×
Zhankui Jia · 1×
Citations per year

Countries citing papers authored by Xuefeng Zang

Since Specialization
Citations

This map shows the geographic impact of Xuefeng Zang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuefeng Zang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuefeng Zang more than expected).

Fields of papers citing papers by Xuefeng Zang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuefeng Zang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuefeng Zang. The network helps show where Xuefeng Zang may publish in the future.

Co-authorship network of co-authors of Xuefeng Zang

This figure shows the co-authorship network connecting the top 25 collaborators of Xuefeng Zang. A scholar is included among the top collaborators of Xuefeng Zang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuefeng Zang. Xuefeng Zang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 3
3 3
4
A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.
3
5 21
6 28
7 21
8 11
9 0
10 7
11 7
12 5
13 32
14 1
15 5
16 19
17 8
18 21
19 10
20 79

About Xuefeng Zang

Xuefeng Zang is a scholar working on Critical Care and Intensive Care Medicine, Anesthesiology and Pain Medicine and Cancer Research, having authored 27 papers that have together received 505 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), Circular RNAs in diseases (4 papers) and Sepsis Diagnosis and Treatment (3 papers). The work is most often cited by research in Cancer Research (189 citations), Critical Care and Intensive Care Medicine (22 citations) and Molecular Biology (275 citations). Xuefeng Zang has collaborated with scholars based in China. Frequent co-authors include Jie Zhen, Xinying Xue, Mingming Meng, Lei Pan, Bo Sheng, Lei Zhao, Yuxia Liu, Yang Liu, Kaifei Wang and Lei Cui. Their work appears in journals such as PLoS ONE, Experimental Neurology and Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026